🇺🇸 FDA
Patent

US 8962631

Compounds useful as inhibitors of ATR kinase

granted A61PA61P31/04A61P35/00

Quick answer

US patent 8962631 (Compounds useful as inhibitors of ATR kinase) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61P, A61P31/04, A61P35/00, A61P43/00